Cellular and molecular mechanisms of metformin: an overview
Open accessThe DOI matches its Crossref record; 167 of the 167 references it cites were found in a registry or an index.
Abstract
Considerable efforts have been made since the 1950s to better understand the cellular and molecular mechanisms of action of metformin, a potent antihyperglycaemic agent now recommended as the first-line oral therapy for T2D (Type 2 diabetes). The main effect of this drug from the biguanide family is to acutely decrease hepatic glucose production, mostly through a mild and transient inhibition of the mitochondrial respiratory chain complex I. In addition, the resulting decrease in hepatic energy status activates AMPK (AMP-activated protein kinase), a cellular metabolic sensor, providing a generally accepted mechanism for the action of metformin on hepatic gluconeogenesis. The demonstration that respiratory chain complex I, but not AMPK, is the primary target of metformin was recently strengthened by showing that the metabolic effect of the drug is preserved in liver-specific AMPK-deficient mice. Beyond its effect on glucose metabolism, metformin has been reported to restore ovarian function in PCOS (polycystic ovary syndrome), reduce fatty liver, and to lower microvascular and macrovascular complications associated with T2D. Its use has also recently been suggested as an adjuvant treatment for cancer or gestational diabetes and for the prevention in pre-diabetic populations. These emerging new therapeutic areas for metformin will be reviewed together with recent findings from pharmacogenetic studies linking genetic variations to drug response, a promising new step towards personalized medicine in the treatment of T2D.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In PCOS, metformin reduces insulin resistance and inhibits ovarian androgen production via effects on steroidogenic acute regulatory protein and 17alphahydroxylase (Diamanti-Kandarakis et al. , 2010; Viollet et al. , 2012).”
From Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis (2015) · cites this paper as Viollet et al., 2012
The cited source says what the claim attributes to it.
In the citing paper
“a drug that is currently being used to treat type II diabetic patients, metformin [74], can activate AMPK”
From Senescence of T Lymphocytes: Implications for Enhancing Human Immunity (2016) · cites this paper as [74]
The cited source says what the claim attributes to it.
In the citing paper
“Given the evidence that metformin acts through the mitochondrial electron transport chain (ETC) by inhibiting complex I(46, 210–212) (Figure 8)”
From Metformin, the Aspirin of the 21st Century: Its Role in Gestational Diabetes Mellitus, Prevention of Preeclampsia and Cancer, and the Promotion of Longevity (2017) · cites this paper as [46]
In the citing paper
“By far the most important mechanism is the reduction in hepatic glucose production that is considered mediated by the activation of the global energy sensor in cells, adenosine monophosphate-activated protein kinase (AMPK) (Figure 1).(46)”
From Metformin, the Aspirin of the 21st Century: Its Role in Gestational Diabetes Mellitus, Prevention of Preeclampsia and Cancer, and the Promotion of Longevity (2017) · cites this paper as [46]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652 · cited 4×
“Thus, AMPK activation by metformin induces the phosphorylation and inactivation of acetyl CoA carboxylase (ACC), an important rate-controlling enzyme for the synthesis of malonylCoA, which is both a critical precursor for the biosynthesis of fatty acids and a potent inhibitor of mitochondrial fatty acid oxidation [17].”
BackgroundInfluentialHyperglycemia and adverse pregnancy outcomes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707943 · Cited by 5,563
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388 · cited 1×
“Furthermore, the authors found a doseresponse relationship between duration of exposure to metformin and cancer incidence [106].”
BackgroundGiovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366
OWEN, M. R., DORAN, E., & HALESTRAP, A. P. (2000) · Biochemical Journal · doi:10.1042/bj3480607 · Cited by 2,157
The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin
Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S.-H., Bardeesy, N., DePinho, R. A., Montminy, M., & Cantley, L. C. (2005) · Science · doi:10.1126/science.1120781 · Cited by 1,950 · cited 25×
“Metformin most likely does not directly activate either LKB1 or AMPK as the drug does not influence the phosphorylation of AMPK by LKB1 in cell-free assay [21].”
BackgroundInfluential
Cited by
Items 501–600 of 1,001
Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis
Le, T., & Loomba, R. S. (2012) · Journal of Clinical and Experimental Hepatology · doi:10.1016/s0973-6883(12)60104-2 · Cited by 45
Polycystic ovary syndrome: chemical pharmacotherapy
Rocca, M. L., Venturella, R., Mocciaro, R., Cello, A. D., Sacchinelli, A., Russo, V. M., Trapasso, S., Zullo, F., & Morelli, M. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1047344 · Cited by 43
Pelantová, H., Bugáňová, M., Holubová, M., Šedivá, B., Zemenová, J., Sýkora, D., Kaválková, P., Haluzík, M., Železná, B., Maletínská, L., et al. (2016) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2016.05.003 · Cited by 42
The emerging role of metformin in gestational diabetes mellitus
Gray, S. G., McGuire, T. M., Cohen, N., & Little, P. J. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12893 · Cited by 40
“The changes in AMP/ATP ratio inhibit gluconeogenesis, as shown in Figure 2.(42) New studies of the effects of metformin on mitochondrial glycerol-3phosphate dehydrogenase (mGPD) show that inhibition of the glycerophosphate shuttle directly blocks gluconeogenesis from glycerol.”
BackgroundInfluentialInsulin priming effect on estradiol-induced breast cancer metabolism and growth
Wairagu, P. M., Phan, A. N., Kim, M.-K., Han, J., Kim, H.-W., Choi, J.-W., Kim, K. W., Cha, S.-K., Park, K. H., & Jeong, Y. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1016660 · Cited by 37
Khodeer, D. M., Zaitone, S. A., Farag, N. E., & Moustafa, Y. M. (2015) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2015-0135 · Cited by 40
Hume, W. E., Shingaki, T., Takashima, T., Hashizume, Y., Okauchi, T., Katayama, Y., Hayashinaka, E., Wada, Y., Kusuhara, H., Sugiyama, Y., et al. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.10.041 · Cited by 40
Metabolomics profiling of metformin-mediated metabolic reprogramming bypassing AMPKα
Yan, M., Qi, H., Xia, T., Zhao, X., Wang, W., Wang, Z., Lu, C., Ning, Z., Chen, H., Li, T., et al. (2018) · Metabolism · doi:10.1016/j.metabol.2018.11.010 · Cited by 42
Park, S., Kim, D., & Kee, S. (2019) · Oncology Letters · doi:10.3892/ol.2019.9892 · Cited by 42
Aseman-Bashiz, E., & Sayyaf, H. (2019) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2019.112285 · Cited by 42
Ma, L., Wang, R., Wang, H., Zhang, Y., & Zhao, Z. (2020) · Food & Nutrition Research · doi:10.29219/fnr.v64.3668 · Cited by 43
Singh, A., Gu, J. J., Zhang, Q., Torka, P., Sundaram, S., Mavis, C. K., & Hernandez‐Ilizaliturri, F. J. (2020) · Cancer & Metabolism · doi:10.1186/s40170-020-00213-w · Cited by 41
Osteogenesis of adipose-derived stem cells from patients with glucose metabolism disorders
Skubis-Sikora, A., Sikora, B., Witkowska, A., Mazurek, U. M., & Gola, J. M. (2020) · Molecular Medicine · doi:10.1186/s10020-020-00192-0 · Cited by 43
Liu, Z., Liao, W., Zhang, Z., Sun, R., Luo, Y., Chen, Q., Li, X., Lu, R., & Ying, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.640347 · Cited by 43
Targeting glucose metabolism to develop anticancer treatments and therapeutic patents
Zhou, Y., Guo, Y., & Tam, K. Y. (2022) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2022.2027912 · Cited by 40
Metformin activates Wnt/β-catenin for the treatment of diabetic osteoporosis
Huang, X., Li, S., Lu, W.-J., & Xiong, L. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-01103-6 · Cited by 41
Jiménez-Amilburu, V., Jong-Raadsen, S. A., Bakkers, J., Spaink, H. P., & Marín‐Juez, R. (2014) · Journal of Endocrinology · doi:10.1530/joe-14-0539 · Cited by 41
Lee, H., Wei, D., & Loeken, M. R. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2451 · Cited by 39
Han, J., Yang, N., Zhang, F., Zhang, C., Liang, F., Xie, W., & Chen, W. (2015) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2015.05.016 · Cited by 39
Guo, Y., Zhang, J., Sun, J., & Gao, H. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116185 · Cited by 41
Lin, D., Zhang, L., Huang, C., & Shao, W. (2026) · iScience · doi:10.1016/j.isci.2026.115024 · Cited by 44
Mancilla, R., Torres, P., Álvarez, C., Schifferli, I., SAPUNAR, J., & Díaz-Bautista, E. (2014) · Revista médica de Chile · doi:10.4067/s0034-98872014000100006 · Cited by 48
Lettieri‐Barbato, D., Vegliante, R., Desideri, E., & Ciriolo, M. R. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.02.003 · Cited by 42
Physiological insights into novel therapies for nephrogenic diabetes insipidus
Sands, J. M., & Klein, J. D. (2016) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00418.2016 · Cited by 39
Wallbillich, J. J., Josyula, S., Saini, U., Zingarelli, R. A., Dorayappan, K. D. P., Riley, M., Wanner, R. A., Cohn, D. E., & Selvendiran, K. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170318 · Cited by 45
Miragem, A. A., & de Bittencourt, P. I. H. (2017) · Human Reproduction Update · doi:10.1093/humupd/dmx020 · Cited by 41
Zhang, J., Xu, H., Zhou, X., Li, Y., Liu, T., Yin, X., & Zhang, B. (2017) · Oncology Letters · doi:10.3892/ol.2017.6877 · Cited by 41
Na, H., Pyo, J.-H., Jeon, H.-J., Park, J., Chung, H., & Yoo, M. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.02.191 · Cited by 43
Targeting Mitochondrial Bioenergetics as a Therapeutic Strategy for Chronic Lymphocytic Leukemia
Chowdhury, S. R., & Banerji, V. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/2426712 · Cited by 39
Antioxidant Versus Pro-Apoptotic Effects of Mushroom-Enriched Diets on Mitochondria in Liver Disease
Fontes, A., Pagès, M. A. I., Oliveira, P. J., Ramalho‐Santos, J., Zischka, H., & Azul, A. M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20163987 · Cited by 40
Metformin and insulin-resistant related diseases: Emphasis on the role of microRNAs
Alimoradi, N., Firouzabadi, N., & Fatehi, R. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111662 · Cited by 39
Advance investigation on synthetic small-molecule inhibitors targeting PD-1/PD-L1 signaling pathway
Awadasseid, A., Wu, Y., & Zhang, W. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119813 · Cited by 40
A Metabolic Pattern in Healthy Subjects Given a Single Dose of Metformin: A Metabolomics Approach
Dahabiyeh, L. A., Mujammami, M. H., Arafat, T., Benabdelkamel, H., Alfadda, A. A., & Rahman, A. M. A. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.705932 · Cited by 43
Mohammad, H. M. F., Gouda, S. G., Eladl, M. A., Elkazaz, A. Y., El-Bayoumi, K. S., Farag, N. E., Elshormilisy, A. A., Alammash, B. B., Hegazy, A., Abdelkhalig, S. M., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114128 · Cited by 43
Metformin delays satellite cell activation and maintains quiescence
Pavlidou, T., Marinkovic, M., Rosina, M., Fuoco, C., Vumbaca, S., Gargioli, C., Castagnoli, L., & Cesareni, G. (2019) · Stem Cells International · doi:10.1155/2019/5980465 · Cited by 38
“Metformin (1,1-dimethylbiguanide hydrochloride) is a calorie restriction mimicking drug that is widely prescribed for the treatment of hyperglycemia in individuals with type II diabetes [18].”
BackgroundMetformin: From diabetes to cancer to prolongation of life
Sirtori, C. R., Castiglione, S., & Pavanello, C. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107367 · Cited by 40
Soga, M., Ohashi, A., Taniguchi, M., Matsui, T., & Tsuda, T. (2014) · FEBS Open Bio · doi:10.1016/j.fob.2014.10.008 · Cited by 38
Ke, J., Liu, Y., Yang, J., Lu, R., Tian, Q., Hou, W., Wang, G., Wei, R., & Hong, T. (2017) · Scientific Reports · doi:10.1038/srep41085 · Cited by 38
Metformin attenuated endotoxin-induced acute myocarditis via activating AMPK
Liu, G., Wu, K., Zhang, L., Dai, J., Huang, W., Lin, L., Ge, P., Luo, F., & Lei, H. (2017) · International Immunopharmacology · doi:10.1016/j.intimp.2017.04.002 · Cited by 40
Kandouli, C., Cassien, M., Mercier, A., Delehedde, C., Ricquebourg, E., Stocker, P., Mekaouche, M., Leulmi, Z., Mechakra, A., Laurent, S., et al. (2017) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2017.06.042 · Cited by 42
Elhadd, T. A., Ponirakis, G., Dabbous, Z., Siddique, M. A., Chinnaiyan, S., & Malik, R. A. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00248 · Cited by 38
Li, Y., Stewart, D. A., Ye, X., Yin, L., Pathmasiri, W., McRitchie, S., Fennell, T. R., Cheung, H., & Sumner, S. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01575 · Cited by 39
Sritawan, N., Suwannakot, K., Naewla, S., Chaisawang, P., Aranarochana, A., Sirichoat, A., Pannangrong, W., Wigmore, P. M., & Welbat, J. U. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112280 · Cited by 41
Metformin Intervention—A Panacea for Cancer Treatment?
Buczyńska, A., Sidorkiewicz, I., Kretowski, A. J., Zbucka-Krętowska, M., & Adamska, A. (2022) · Cancers · doi:10.3390/cancers14051336 · Cited by 41
Action Mechanism of Metformin and Its Application in Hematological Malignancy Treatments: A Review
Zhang, Y., Zhou, F., Guan, J., Zhou, L., & Chen, B. (2023) · Biomolecules · doi:10.3390/biom13020250 · Cited by 41
Cells of Origin in Skin Cancer
Becker, J. C., & Hausen, A. Z. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.233 · Cited by 37
Kanadiya, M. K., Gohel, T. D., Sanaka, M. R., Thota, P. N., & Shubrook, J. H. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.04.010 · Cited by 37
He, X. M., Chen, X., Wang, L., Wang, W., Liang, Q., Yi, L., Wang, Y., & Gao, Q. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.09.024 · Cited by 38
The zebrafish model of tuberculosis - no lungs needed
Bouz, G., & Hasawi, N. A. (2018) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2018.1523132 · Cited by 37
Toxicity of Metformin and Hypoglycemic Therapies
Akhter, M. S., & Uppal, P. (2020) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2019.08.004 · Cited by 40
A Fbxo48 inhibitor prevents pAMPKα degradation and ameliorates insulin resistance
Liu, Y., Jurczak, M. J., Lear, T., Lin, B., Larsen, M. B., Kennerdell, J. R., Chen, Y., Huckestein, B. R., Nguyen, M. K., Tuncer, F., et al. (2021) · Nature Chemical Biology · doi:10.1038/s41589-020-00723-0 · Cited by 41
Hypoglycemic natural products with in vivo activities and their mechanisms: a review
Ma, W., Xiao, L., Liu, H., & Hao, X. (2022) · Food Science and Human Wellness · doi:10.1016/j.fshw.2022.04.001 · Cited by 38
The Role of Gut Microbiota in High-Fat-Diet-Induced Diabetes: Lessons from Animal Models and Humans
Qi, Y., & Wang, X. (2023) · Nutrients · doi:10.3390/nu15040922 · Cited by 38
Report of the JDS/JCA Joint Committee on Diabetes and Cancer
Kasuga, M., Ueki, K., Tajima, N., Noda, M., Ohashi, K., Noto, H., Goto, A., Ogawa, W., Sakai, R., Tsugane, S., et al. (2013) · Diabetology International · doi:10.1007/s13340-013-0121-3 · Cited by 37
Pharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS
Cignarella, A., Mioni, R., Sabbadin, C., Dassie, F., Parolin, M., Vettor, R., Barbot, M., & Scaroni, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249554 · Cited by 36
Metformin and HER2-positive breast cancer: Mechanisms and therapeutic implications
Bashraheel, S. S., Kheraldine, H., Khalaf, S., & Moustafa, A. A. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114676 · Cited by 38
Wen, Q., Fang, S., Liang, Y., Tian, Y., Chen, Y., Yuan, J., & Qiu, C. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1156521 · Cited by 39
Vitamin B12 deficiency in diabetic patients treated with metformin: A narrative review
Zoubi, M. S. A., Kreasha, R. A., Aqel, S., Saeed, A., Al-Qudimat, A. R., & Al‐Zoubi, R. M. (2024) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-024-03634-4 · Cited by 41
Ovarian Aging: Mechanisms, Age‐Related Disorders, and Therapeutic Interventions
Liu, X., Zhao, Y., Feng, Y., Wang, S., & Zhang, J. (2025) · MedComm · doi:10.1002/mco2.70481 · Cited by 46
Ma, Y., Rao, Z., Shi, A., Wang, Y.-F., Huang, J., Han, M., Wang, X.-D., Jin, Y.-W., Zhang, G., Zhou, Y., et al. (2015) · Journal of Chromatographic Science · doi:10.1093/chromsci/bmv097 · Cited by 37
Lee, Z., Teo, X.-Y., Song, Z. J., Nin, D. S., Novera, W., Choo, B. A., Dymock, B. W., Moore, P. K., Huang, R. Y., & Deng, L. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00763 · Cited by 38
Biondo, L. A., Batatinha, H., de Souza, C. O., Teixeira, A. A. D. S., Silveira, L. S., Alonso‐Vale, M. I. C., Oyama, L. M., Alves, M. J., Seelaender, M. C. L., & Neto, J. C. R. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00452 · Cited by 39
Mao, C.-F., Zhang, X., Johnson, A., He, J., & Kong, Z. (2018) · BioMed Research International · doi:10.1155/2018/4237354 · Cited by 49
Petrera, M., Paleari, L., Clavarezza, M., Puntoni, M., Caviglia, S., Briata, I. M., Oppezzi, M., Mislej, E. M., Štabuc, B., Gnant, M., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-5126-7 · Cited by 39
A traceable nanoplatform for enhanced chemo-photodynamic therapy by reducing oxygen consumption
Yao, H., Zhang, S., Guo, X., Li, Y., Ren, J., Zhou, H., Du, B., & Zhou, J. (2019) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2019.03.001 · Cited by 37
Baghdadi, L. R. (2020) · PLoS ONE · doi:10.1371/journal.pone.0235637 · Cited by 38
Gao, H., Ding, L., Liu, R., Zheng, X., Xia, X., Wang, F., Qi, J., Tong, W., & Qiu, Y. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.02.217 · Cited by 36
Dong, X., Hui, T., Chen, J., Zheng, Y., Ren, D., Zou, S., Wang, S., Fei, E., Jiao, H., & Lai, X. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.642908 · Cited by 36
Lee, B. H., Indran, I. R., Tan, H. M., Li, Y., Zhang, Z., Li, J., & Yong, E.-L. (2016) · Endocrinology · doi:10.1210/en.2015-1733 · Cited by 35
Zakikhani, M., Bazile, M., Hashemi, S., Javeshghani, S., Avizonis, D., Pierre, J. S., & Pollak, M. N. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049513 · Cited by 35
Shokri, F., Ghaedi, H., Ghafouri‐Fard, S., Movafagh, A., Abediankenari, S., Mahrooz, A., Kashi, Z., & Omrani (2016) · PubMed Central · Cited by 36
Subramaniam, A., Landstrom, M., LUU, A., & Hayes, K. C. (2018) · Nutrients · doi:10.3390/nu10020235 · Cited by 36
Colorectal and Prostate Cancer Risk in Diabetes: Metformin, an Actor Behind the Scene
Anwar, M. A., Kheir, W. A., Eid, S., Fares, J., Liu, X., Eid, A. H., & Eid, A. A. (2014) · Journal of Cancer · doi:10.7150/jca.9726 · Cited by 35
Haber, R., Zarzour, F., Ghezzawi, M., Saadeh, N., Bacha, D. S., Jebbawi, L. A., Chakhtoura, M., & Mantzoros, C. S. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15501 · Cited by 39
mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib
Hanly, E. K., Bednarczyk, R. B., Tuli, N. Y., Moscatello, A. L., Halicka, H. D., Li, J., Geliebter, J., Darżynkiewicz, Z., & Tiwari, R. K. (2015) · Oncotarget · doi:10.18632/oncotarget.4052 · Cited by 37
Eid, H. M., Thong, F. S. L., Nachar, A., & Haddad, P. S. (2017) · Pharmaceutical Biology · doi:10.1080/13880209.2017.1345952 · Cited by 38
Bao, X., Zhao, L., Guan, H., & Li, F. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0620-z · Cited by 35
Latorre, J., Ortega, F. J., Liñares‐Pose, L., Moreno‐Navarrete, J. M., Lluch, A., Comas, F., Oliveras‐Cañellas, N., Ricart, W., Höring, M., Zhou, Y., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102697 · Cited by 35
Fertility-Sparing Treatment for Early-Stage Cervical, Ovarian, and Endometrial Malignancies
Nitecki, R., Woodard, T. L., & Rauh‐Hain, J. A. (2020) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000004163 · Cited by 35
Obesity Connected Metabolic Changes in Type 2 Diabetic Patients Treated With Metformin
Aleidi, S. M., Dahabiyeh, L. A., Gu, X., Dubayee, M. A., Alshahrani, A. S., Benabdelkamel, H., Mujammami, M. H., Li, L., Aljada, A., & Rahman, A. M. A. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.616157 · Cited by 40
Targeting Energy Expenditure—Drugs for Obesity Treatment
Jimenez-Munoz, C. M., López, M., Albericio, F., & Makowski, K. (2021) · Pharmaceuticals · doi:10.3390/ph14050435 · Cited by 35
Expression of 4E-BP1 in juvenile mice alleviates mTOR-induced neuronal dysfunction and epilepsy
Nguyen, L. H., Xu, Y., Mahadeo, T., Zhang, L., Lin, T. V., Born, H. A., Anderson, A. E., & Bordey, A. (2022) · Brain · doi:10.1093/brain/awab390 · Cited by 35
Chemoprevention of oral cancer: A review and future perspectives
Liao, Y., Chou, W., Chang, C., Lin, M., Wang, C., Lou, P., & Chen, T. (2023) · Head & Neck · doi:10.1002/hed.27301 · Cited by 36
New hope for tumor immunotherapy: the macrophage-related “do not eat me” signaling pathway
Deng, H. Y., Wang, G., Zhao, S., Tao, Y., Zhang, Z., Yang, J., & Lei, Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1228962 · Cited by 39
Metformin inhibits food intake and neuropeptide Y gene expression in the hypothalamus.
Duan, Y., Zhang, R., Zhang, M., Sun, L., Dong, S., Wang, G., Zhang, J., & Zhao, Z. Y. (2013) · PubMed Central · doi:10.3969/j.issn.1673-5374.2013.25.009 · Cited by 39
ter Horst, K. W., Gilijamse, P. W., Ackermans, M. T., Soeters, M. R., Nieuwdorp, M., Romijn, J. A., & Serlie, M. J. M. (2016) · Metabolism · doi:10.1016/j.metabol.2016.02.010 · Cited by 40
Malin, S. K., Liu, Z., Barrett, E. J., & WELTMAN, A. L. (2016) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-016-9352-5 · Cited by 39
Protic, D., Aydin, E. Y., Tassone, F., Tan, M. M., Hagerman, R. J., & Schneider, A. (2019) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.745 · Cited by 34
Vaughan, R. A., Mermier, C. M., Bisoffi, M., Trujillo, K. A., & Conn, C. A. (2014) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-013-0301-4 · Cited by 34
Cantoria, M. J., Boros, L. G., & Meuillet, E. J. (2013) · Metabolomics · doi:10.1007/s11306-013-0555-4 · Cited by 34
Suhaimi, N.-A. M., Phyo, W. M., Yap, H. Y., Choy, S. H. Y., Wei, X., Choudhury, Y., Tan, W. J., Tan, L. A. P. Y., Foo, R., Tan, S. H. S., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0793 · Cited by 37
Effects of metformin on endothelial health and erectile dysfunction
Patel, J. P., Lee, E. H., Mena, C. I., & Walker, C. N. (2017) · Translational Andrology and Urology · doi:10.21037/tau.2017.03.52 · Cited by 39
Ahn, M., & Cho, G. (2017) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.1584 · Cited by 34
Kupreeva, M., Diané, A., Lehner, R. S., Watts, R., Ghosh, M., Proctor, S. D., & Vine, D. F. (2018) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00018.2018 · Cited by 36
Shikuma, C. M., Chew, G. M., Kohorn, L. B., Souza, S. A., Chow, D. C., SahBandar, I. N., Park, E. Y., Hanks, N., Gangcuangco, L. M. A., Gerschenson, M., et al. (2019) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2019.0078 · Cited by 34
Yousuf, Y., Datu, A., Barnes, B., Amini‐Nik, S., & Jeschke, M. G. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1480-x · Cited by 36
Metabolic Targeting of Cancer Stem Cells
Mukha, A., & Dubrovska, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.537930 · Cited by 35
Kim, E., Cui, J., Kang, I., Zhang, G., & Lee, Y. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18031367 · Cited by 35
García‐Viñuales, S., Sciacca, M. F. M., Lanza, V., Santoro, A. M., Grasso, G., Tundo, G. R., Sbardella, D., Coletta, M., Grasso, G., Rosa, C. L., et al. (2021) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2021.105072 · Cited by 35
Almatrafi, S. B., Bakr, E.-S. H., Almatrafi, A. A., & Altayeb, M. M. (2022) · Human Nutrition & Metabolism · doi:10.1016/j.hnm.2022.200138 · Cited by 40
Metadata
- Authors
- Viollet, B., Guigas, B., Garcia, N. S., Leclerc, J., Foretz, M., & Andreelli, F.
- Affiliations
- INSERM, U1016, Institut Cochin, Paris, France
- Leiden University Medical Center (NL)
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Leclerc, Jocelyne
- Foretz, Marc
- Venue
- Clinical Science
- Publisher
- Portland Press Ltd.
- Published
- 2011-11-11
- Volume
- 122
- Issue
- 6
- Pages
- 253-270
- ISSN
- 0143-5221 (ISSN-L)
- 1470-8736
- PMC
- PMC3398862
- OpenAlex
- W2154024784
- Cited by
- 1,720
- References
- 167
- Citations by year
- 2026: 63 · 2025: 85 · 2024: 96 · 2023: 103 · 2022: 106 · 2021: 143 · 2020: 155 · 2019: 135 · 2018: 141 · 2017: 156 · 2016: 137 · 2015: 144 · 2014: 117 · 2013: 104 · 2012: 34
- FWCI
- 7.43
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion, other-oa)
- Leiden Repository (Leiden University) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
- Keywords
- metformin, type 2 diabetes, biguanides, AMPK, mitochondrial complex I inhibition, hepatic gluconeogenesis, hepatic glucose production, polycystic ovary syndrome, hepatic steatosis, diabetes complications, adjuvant cancer therapy, gestational diabetes mellitus, prediabetes, pharmacogenetics, personalized medicine
- MeSH terms
- Animals, Cardiovascular System, Diabetic Nephropathies, Female, Humans, Hypoglycemic Agents, Metformin, Neoplasms, Polycystic Ovary Syndrome, Circadian Clocks
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.